Trial Profile
A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Alogliptin/metformin (Primary) ; Alogliptin/pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 13 Feb 2018 Status changed from recruiting to discontinued because of buisness decision;no safety or efficacy concerns.
- 08 Feb 2017 Status changed from not yet recruiting to recruiting.
- 14 Dec 2016 New trial record